Log in

NYSEARCA:IHEiShares US Pharmaceuticals ETF Stock Price, Forecast & News

+1.02 (+0.65 %)
(As of 06/5/2020 04:00 PM ET)
Today's Range
Now: $157.37
50-Day Range
MA: $152.61
52-Week Range
Now: $157.37
Volume22,586 shs
Average Volume21,256 shs
Market Capitalization$361.95 million
P/E RatioN/A
Dividend Yield1.45%
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund's investment advisor is BlackRock Fund Advisors.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.87 out of 5 stars

Basic Details

Issuer iShares
Fund NameiShares US Pharmaceuticals ETF
Tax ClassificationRegulated Investment Company
Inception Date5/1/2006
Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason

Fund Focus

Asset ClassEquity
BenchmarkDow Jones US Select Pharmaceuticals Index
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$360.19 million
Average Daily Volume$26,118.70

ETF Expenses

Management Fee0.44%
Other Expenses0.00%
Total Expenses0.44%
Fee Waiver0.00%
Net Expenses0.44%

Administrator, Advisor and Custodian

AdministratorState Street Bank and Trust Company
AdvisorBlackRock Fund Advisors
CustodianState Street Bank and Trust Company
DistributorBlackRock Investments, LLC
Transfer AgentState Street Bank and Trust Company
Lead Market MakerIMC Chicago

Receive IHE News and Ratings via Email

Sign-up to receive the latest news and ratings for IHE and its competitors with MarketBeat's FREE daily newsletter.

Geographic Exposure of iShares US Pharmaceuticals ETF (NYSEARCA:IHE)
Currency Exposure of iShares US Pharmaceuticals ETF (NYSEARCA:IHE)
Sector Exposure of iShares US Pharmaceuticals ETF (NYSEARCA:IHE)
Industry Exposure of iShares US Pharmaceuticals ETF (NYSEARCA:IHE)

iShares US Pharmaceuticals ETF (NYSEARCA:IHE) Frequently Asked Questions

How has iShares US Pharmaceuticals ETF's stock been impacted by COVID-19 (Coronavirus)?

iShares US Pharmaceuticals ETF's stock was trading at $138.60 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IHE stock has increased by 13.5% and is now trading at $157.37. View which stocks have been most impacted by Coronavirus.

How often does iShares US Pharmaceuticals ETF pay dividends? What is the dividend yield for iShares US Pharmaceuticals ETF?

iShares US Pharmaceuticals ETF declared a quarterly dividend on Wednesday, March 25th. Investors of record on Thursday, March 26th will be paid a dividend of $0.5866 per share on Tuesday, March 31st. This represents a $2.35 annualized dividend and a dividend yield of 1.49%. The ex-dividend date is Wednesday, March 25th. This is an increase from iShares US Pharmaceuticals ETF's previous quarterly dividend of $0.51. View iShares US Pharmaceuticals ETF's dividend history.

Has iShares US Pharmaceuticals ETF been receiving favorable news coverage?

News headlines about IHE stock have trended positive on Saturday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. iShares US Pharmaceuticals ETF earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutiShares US Pharmaceuticals ETF.

What other stocks do shareholders of iShares US Pharmaceuticals ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iShares US Pharmaceuticals ETF investors own include Adobe (ADBE), Broadcom (AVGO), Alibaba Group (BABA), Baxter International (BAX), Baidu (BIDU), Biogen (BIIB), Brooks Automation (BRKS), Chemours (CC), Caesars Entertainment (CZR) and DXC Technology (DXC).

Who are iShares US Pharmaceuticals ETF's key executives?

iShares US Pharmaceuticals ETF's management team includes the following people:
  • George G. C. Parker Ph.D., Independent Chairman of the Board of Trustees (Age 78)
  • Michael Arthur Latham, President, Trustee (Age 51)
  • Jack Gee, Chief Financial Officer, Treasurer (Age 57)
  • Geoffrey D. Flynn, Chief Operating Officer, Executive Vice President
  • Amy Schioldager, Executive Vice President (Age 56)
  • Ira P. Shapiro, Vice President, Chief Legal Officer (Age 52)
  • Matt Tucker, Vice President
  • Eilleen M. Clavere, Secretary (Age 61)
  • Cecilia H. Herbert, Independent Trustee (Age 68)
  • Charles A. Hurty, Independent Trustee (Age 73)

What is iShares US Pharmaceuticals ETF's stock symbol?

iShares US Pharmaceuticals ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "IHE."

Who are iShares US Pharmaceuticals ETF's major shareholders?

iShares US Pharmaceuticals ETF's stock is owned by many different institutional and retail investors. Top institutional investors include Morgan Stanley (1.82%), Morgan Stanley (1.89%), Raymond James & Associates (0.93%), Murphy Capital Management Inc. (0.90%), Commonwealth Equity Services LLC (0.60%) and Wells Fargo & Company MN (0.55%).

Which major investors are selling iShares US Pharmaceuticals ETF stock?

IHE stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Morgan Stanley, Morgan Stanley, Murphy Capital Management Inc., Cetera Advisor Networks LLC, Wells Fargo & Company MN, Commonwealth Equity Services LLC, and Spinnaker Trust.

Which major investors are buying iShares US Pharmaceuticals ETF stock?

IHE stock was purchased by a variety of institutional investors in the last quarter, including Raymond James & Associates, S. R. Schill & Associates, Advisor Group Holdings Inc., Janney Montgomery Scott LLC, Envestnet Asset Management Inc., Wealthstreet Investment Advisors LLC, UBS Group AG, and Centaurus Financial Inc..

How do I buy shares of iShares US Pharmaceuticals ETF?

Shares of IHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is iShares US Pharmaceuticals ETF's stock price today?

One share of IHE stock can currently be purchased for approximately $157.37.

How big of a company is iShares US Pharmaceuticals ETF?

iShares US Pharmaceuticals ETF has a market capitalization of $361.95 million.

What is iShares US Pharmaceuticals ETF's official website?

The official website for iShares US Pharmaceuticals ETF is www.iShares.com.

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.